Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system

Journal of Neurology, Neurosurgery, and Psychiatry
Sven GläskerH P Neumann

Abstract

Cerebellar haemangioblastoma occurs sporadically or as a component tumour of autosomal dominant von Hippel-Lindau disease. Biallelic inactivation of the VHL tumour suppressor gene, which is located on chromosome 3p, has been shown to be involved in the pathogenesis of both tumour entities. Mechanisms of VHL inactivation are intragenic mutations, mitotic recombination events, and hypermethylation of the promoter region. The systematic and complete examination of these genetic and epigenetic phenomena in large series of von Hippel-Lindau disease related and sporadic hemangioblastomas has, thus far, not been performed. In the largest series to date, 29 von Hippel-Lindau disease associated and 13 sporadic haemangioblastomas were investigated for all suggested inactivating mechanisms of the VHL gene using single strand conformational polymorphism (SSCP), loss of heterozygosity (LOH), and methylation analyses. Additionally, corresponding blood samples of all patients were screened for VHL germline mutations by SSCP and Southern blotting. Germline mutations were identified in 94% of patients with von Hippel-Lindau disease and their tumours and 62% of these hemangioblastomas showed LOH of chromosome 3p. Of the 13 sporadic tumours, 23% ...Continue Reading

References

May 1, 1992·Human Molecular Genetics·M H JonesY Nakamura
Apr 1, 1995·Brain Pathology·H P NeumannB Zbar
May 1, 1994·Nature Genetics·J R GnarraF M Duh
Mar 14, 1998·Proceedings of the National Academy of Sciences of the United States of America·A PauseR D Klausner
Jul 29, 1998·Journal of Internal Medicine·H P Neumann, B U Bender
Oct 15, 1998·Proceedings of the National Academy of Sciences of the United States of America·S V IvanovM I Lerman
Feb 13, 1999·Nature Genetics·P A Jones, P W Laird
Nov 24, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·S GläskerH P Neumann

❮ Previous
Next ❯

Citations

Mar 17, 2009·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Jing-Shan HuangChi-Jung Huang
Feb 13, 2013·Acta Neuropathologica·Alexander O VortmeyerEdward H Oldfield
Sep 29, 2006·Journal of Human Genetics·Maddalena MartellaAlessandra Murgia
Jun 30, 2004·The American Journal of Surgical Pathology·Michal MichalKarep Koudepa
May 21, 2005·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Johanna GijtenbeekJudith Jeuken
Jan 1, 2004·Hereditary Cancer in Clinical Practice·Cezary CybulskiJan Lubiński
Aug 28, 2004·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Desanka TasićIrena Dimov
Aug 12, 2014·Current Neurology and Neuroscience Reports·Sophie TaillibertMarc C Chamberlain
Apr 4, 2015·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Marie Louise Mølgaard BinderupMarie Luise Bisgaard
Sep 7, 2007·Journal of Neuropathology and Experimental Neurology·Sebsebe LemetaKirsti Husgafvel-Pursiainen
Dec 18, 2013·Journal of Neuropathology and Experimental Neurology·Lucia Anna MuscarellaLeonardo D'Agruma
Jan 11, 2011·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·M M BeitnerK J Drummond
Jun 9, 2009·Medicina clínica·María Delgado CapelPablo Cannata
Feb 2, 2006·Neurosurgery Clinics of North America·John H ChiAndrew T Parsa
Jun 1, 2007·European Journal of Clinical Investigation·J S HuangC M Lin
Nov 2, 2005·Annals of Neurology·Sven GläskerZhengping Zhuang
Jan 16, 2015·Acta Neuropathologica Communications·Ganesh M ShankarDaniel P Cahill
Sep 24, 2015·Orphanet Journal of Rare Diseases·Virginia AlbiñanaLuisa María Botella
Dec 22, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Y Kim, William G Kaelin
Apr 27, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sarah M NielsenRachel H Giles
Dec 1, 2017·Advances in Anatomic Pathology·Michele BiscegliaCarlos E Bacchi
Feb 28, 2016·Familial Cancer·Roeliene C KruizingaAnnemiek M E Walenkamp
Oct 18, 2013·Endocrine-related Cancer·Roeliene C KruizingaThera P Links
Mar 27, 2013·Nature Reviews. Neurology·Patricia L ZadnikChetan Bettegowda
Oct 31, 2015·Journal of Neuro-oncology·David TaïebPhilippe Metellus
Dec 24, 2014·Nature Reviews. Cancer·Lucy GossageEamonn R Maher
Nov 13, 2004·Journal of Neuropathology and Experimental Neurology·Sebsebe LemetaTom Böhling

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.